# Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer

> **NCT04733118** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **MedSIR** · enrollment: 393 (actual)

## Conditions studied

- Early Breast Cancer

## Interventions

- **DRUG:** Trastuzumab and Pertuzumab (FDC SC) and T-DM1

## Key facts

- **NCT ID:** NCT04733118
- **Lead sponsor:** MedSIR
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-08-05
- **Primary completion:** 2027-03
- **Final completion:** 2028-03
- **Target enrollment:** 393 (ACTUAL)
- **Last updated:** 2026-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04733118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04733118, "Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04733118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*